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Toxic Oil Timeline
Diagnosing Effects Decades Later 
Two decades after contaminated cooking oil caused widespread sick-
ness in Spain, patients with so-called toxic oil syndrome (TOS) con-
tinue to report neurologic symptoms. Accurately assessing these
symptoms—which include headache, insomnia, and muscle weak-
ness—has been challenging, because the symptoms are numerous and
tend to be vague. Standard clinical examinations have detected few or
no problems, and patients have sometimes been accused of exaggerat-
ing or malingering. This month, a team led by Manuel Posada de la
Paz of the Instituto de Salud Carlos III in Madrid provides the first
quantitative evidence that TOS patients do indeed experience neuro-
logic abnormalities [EHP 111:1326–1334]. 
In May 1981, Spanish health officials were puzzled and alarmed
by the emergence of a severe, possibly novel respiratory illness. The
outbreak, which occurred in Madrid and the northwestern Spanish
provinces, affected 10,000 people and claimed at least 80 lives in the
first month. Initial symptoms included fluid in the lungs, shortness
of breath, fever, headache, rash, muscle pain, and a proliferation of
eosinophils (a type of white blood cell). An infectious agent seemed
implicated, but by mid-June epidemiologic studies revealed the cause
to be cooking oil derived from aniline-denatured rapeseed oil. This
oil had been produced for industrial uses but was illegally refined to
remove the aniline and sold as pure olive oil. The Spanish govern-
ment acted quickly to remove all suspect oil from the market, but
TOS eventually affected at least 20,000 people and caused more than
300 deaths. 
Even after the cause was identified, the crisis continued. TOS
comprises three phases: the early acute phase, an intermediate phase
involving neurologic complaints and intense muscle pain, and, for
approximately 60% of victims, a chronic phase marked by motor and
sensory nerve disorders and muscle pain and cramping. Researchers
strongly suspect that unknown toxic compounds created during refin-
ing triggered autoimmune disease.
In general, the difficulty in assessing TOS-related neurologic symp-
toms arises from the vagueness and subtlety of those symptoms. A pos-
sible solution rests with quantitative neurologic testing methods that
have been developed since the late 1980s and used to detect subtle
nerve damage associated with other diseases. These neurobehavioral
tests include computerized examination of the central, peripheral, and
autonomic nervous systems and use of a “vibrotactile threshold” as a
measure of large myelinated nerve fiber function. This study was the
first time such tests have been used with TOS patients.
The researchers recruited a random sample of TOS patients who
lived in the Alcorcón locality of Madrid province in 1981 and assem-
bled an age- and sex-matched referent group from the same area. All
participants completed a questionnaire covering neurologic symp-
toms, environmental exposures, demographics, and other factors.
Participants also underwent clinical examination and completed
neurobehavioral testing.
Analysis of the neurobehavioral data revealed significant differences
between the groups. The TOS group had higher incidences of muscle
cramps and spasms; abnormal sensations such as numbness, burning,
and paresthesias; loss of strength; diminished sensitivity to stimulus
(hypoesthesias); poor coordination; headache; sleep disturbances; and
memory loss. Female TOS patients over 35 were most affected, and
some group differences (such as hypoesthesias) were significant only for
women. The standard clinical neurologic examination did not reveal
any differences aside from increased upper-limb pain and diminished
lower-limb sensation in the TOS group. Questionnaire data uncovered
no significant differences in neurologic history between the groups. 
The researchers suggest that quantitative neurologic testing could
help track symptom development over time, not only with TOS but in
other hard-to-document neurologic diseases as well. –Julia R. Barrett
Setting the Stage for Illness
Mercury Exposure and Autoimmune Disease
The current scientific literature abounds with studies of the strongly
suspected link between exposure to inorganic mercury (iHg) and
autoimmune disease, a family of often debilitating and sometimes
fatal conditions. Although no human association has been document-
ed, the connection is well known in animal models. A great deal of
work continues to characterize the complex physiologic mechanisms
involved and thereby shed light on the role of environmental mercury
exposures in the etiology of these illnesses. Now a team of Maryland
investigators has found that even brief, low-level environmental mer-
cury exposure may increase susceptibility to autoimmune disease in
mice [EHP 111:1273–1277]. 
iHg experiments often use mice bred for susceptibility to various
autoimmune diseases. In this study, however, the team used healthy,
genetically nonsusceptible mice. The researchers injected treatment
groups of 6- to 8-week-old female B6D2F1 mice with iHg doses of 20
or 200 micrograms per kilogram dissolved in water. The mice were
dosed every other day for 15 days, for a total of 8 doses. Control ani-
mals were injected with an equal total volume of sodium chloride.
Five days after cessation of the iHg injections, both case and control
mice were intravenously administered spleen cells from another mouse
strain to induce chronic graft-versus-host disease (GVHD), a well-
established murine model of acquired autoimmunity.
This study involved very low exposures compared to those com-
monly used in studies of iHg immunotoxicity (typically 500–2,000
micrograms per kilogram). These low doses helped avoid confounding
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A slippery slope. Research shows that the health effects of exposure
to contaminated cooking oil persist decades after the initial event.Science Selections
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of the subsequent results by the toxic effects of iHg exposure itself or by
directly causing iHg-associated autoimmune disease. 
The dose of parental donor cells was set just above the threshold
for consistent induction of chronic GVHD, and under normal condi-
tions would be expected to induce a mild case of the lupuslike condi-
tion, as it did in the controls. In the case mice, however, the scientists
determined that the iHg pretreatment clearly accelerated and exacer-
bated the course of the disease.
Unlike the control mice, the iHg-exposed mice experienced
glomerulonephritis (an inflammatory kidney disease) and elevated
urine protein, evidence of accelerated GVHD. The glomerulonephri-
tis, in turn, resulted in accelerated mortality in the iHg-treated groups.
Upon reexamination 2–3 months after disease induction, autoanti-
bodies characteristic of chronic GVHD were found to have become
significantly elevated in surviving iHg-treated mice, but no markers
characteristic of iHg-associated autoimmunity were seen. These results
imply that the iHg treatment affected the acquired autoimmune dis-
ease itself—that the disease was not caused by delayed effects of the
iHg exposure, but that its course was worsened by the exposure.
The results of the study, the first of its kind, support the hypothe-
sis that low-level environmental exposure to mercury is a potential fac-
tor in the development of autoimmune disease in humans.
Disturbingly, these results further suggest that “low-level exposure . . .
may lower the threshold for disease development in susceptible indi-
viduals who later encounter the appropriate infectious or toxic triggers
of disease.” If these findings are confirmed by replication and further
research, the implications regarding safe thresholds for environmental
mercury exposure could be profound. –Ernie Hood
ALS and Lead
The Polymorphism Possibility
Although the etiology of amyotrophic lateral sclerosis (ALS), an often
fatal neurodegenerative disease, is still largely unexplained, research
suggests that lead exposure may be a risk factor. Freya Kamel of the
NIEHS earlier led a group that identified a potential role of lead
exposure in the etiology of ALS. Now she and her colleagues have
taken that work a step further, examining the possible association of
ALS risk with specific genetic polymorphisms known to affect lead
toxicokinetics [EHP 111:1335–1339].
The researchers used data from a case–control study conducted in
New England between 1993 and 1996 that involved more than 100
ALS patients and 38 control subjects. The study participants com-
pleted questionnaires on demographic and lifestyle characteristics,
and were invited to provide tissue samples for measurement of blood
and bone lead concentrations. For this analysis, DNA genotyping was
performed using blood samples from the original study. 
In many adults with no known recent environmental exposure
(including most of the subjects in the study), internal lead exposure—
that is, the migration of stored lead from bone into the blood—is the
major source of blood lead. The researchers speculated that polymor-
phisms of two genes—ALAD (which codes for ∂-aminolevulinic acid
dehydratase, an enzyme involved in heme synthesis in red blood cells)
and VDR (which codes for the vitamin D receptor)—might confer
increased susceptibility to ALS through their previously confirmed
impact on lead retention or mobilization in bone and blood. 
Kamel and colleagues found that the variant allele (ALAD 2) of
the polymorphism denoted as ALAD K59N was positively associated
with an approximate twofold increase in risk of ALS after adjustment
for age, sex, region, education, and physical activity. In the course of
their analysis, they also identified a previously unknown polymor-
phism, denoted as ALAD IVS2+299G>A. The variant allele of that
polymorphism (ALAD I2-2) was found, after similar adjustment, to
be negatively associated with ALS risk. Both alleles were positively
associated with decreased bone lead concentrations, and neither affect-
ed the relationship of blood or bone lead to ALS. No ALS risk associa-
tions were found with the alleles of the VDR polymorphism, nor did
it appear to be associated with blood or bone lead concentrations. 
The researchers theorize that although ALAD alleles did not mod-
ify the relationship of ALS to lead in this cross-sectional study, genetic
susceptibility conferred by these polymorphisms might still affect risk
through a mechanism related to internal lead exposure. ALAD 2
appears to promote retention of lead in blood and migration of lead
from bone to blood. The current findings are consistent with the
hypothesis that this increased retention of lead in blood relative to
bone increases its availability to target tissues and hence its toxicity.
The authors speculate that “alterations in lead toxicokinetics con-
ferred by the presence of the ALAD 2 allele may subtly increase expo-
sure to lead throughout a person’s lifetime, thereby elevating risk.” 
The authors point out that the study is limited by a low participa-
tion rate of control subjects (41%) in providing tissue samples,
although a much higher percentage completed the questionnaire,
leading to concerns about selection bias and contributing to impreci-
sion in the statistical evaluation of relationships. They conclude that
because the study is small and the observation unique, further
research is necessary to confirm or refute the hypothesis. Considering
that the frequency of the ALAD 2 allele is approximately 10% in
Caucasian populations, if this study’s conclusions are confirmed, it
will be an important contribution to identifying a large number of
people who could be at elevated risk for developing a devastating,
incurable disease. –Ernie Hood
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Origins of disease? A gene polymorphism that promotes the migra-
tion of lead from bone to blood and the retention of lead in blood
may increase the risk of ALS.